Supernus Pharmaceuticals (SUPN) Receives Tentative FDA Approval
Tweet Send to a Friend
Down)
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) received a tentative approval letter from the FDA for Trokendi XR™, a once-daily extended release formulation of topiramate (formerly known as SPN-538).
The letter states that the FDA completed its review of the Trokendi XR NDA and that no additional clinical trials are required. Our initial understanding is that final approval is conditioned on resolving a marketing exclusivity issue raised by the FDA regarding a specific pediatric population.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The letter states that the FDA completed its review of the Trokendi XR NDA and that no additional clinical trials are required. Our initial understanding is that final approval is conditioned on resolving a marketing exclusivity issue raised by the FDA regarding a specific pediatric population.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Supernus to Present at Two Investor Conferences
- Peregrine Pharma (PPHM), FDA Reach Agreement Over Bavituximab Phase III Design
- Despite Massive Moves in Solar Stocks, Boon Times are Cleary Not Here (FSLR) (JASO) (SCTY) (RSOL)
Create E-mail Alert Related Categories
FDA, Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
